home / stock / agle / agle news

AGLE News and Press, Aeglea BioTherapeutics Inc. From 09/02/20

Stock Information
Company Name: Aeglea BioTherapeutics Inc.
Stock Symbol: AGLE
Market: NASDAQ
Website: aegleabio.com
Menu
AGLE AGLE Quote AGLE Short AGLE News AGLE Articles AGLE Message Board
Get AGLE Alerts

News, Short Squeeze, Breakout and More Instantly...
AGLE - Aeglea BioTherapeutics to Participate in September Investment Conferences

AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate ...
AGLE - Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate i...

AGLE - Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights

Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at  56 Week Analysis of Phase 1/2 Open-Label Extension Study Initiated Phase 1/2 Clinical Trial of ACN00177 for the Treatment of Homocystinuria AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSW...

AGLE - Aeglea BioTherapeutics to Present at BIO Digital 2020

AUSTIN, Texas, June 01, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will provide a cor...
AGLE - Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020

AUSTIN, Tx., May 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced that, due to the public ...

AGLE - Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

   Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with Previously Reported Results AUSTIN, Texas, May 26, 2020 (GLOBE NEWSWIRE) --...

AGLE - Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

AUSTIN, Texas, May 19, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will present a new ...
AGLE - Aeglea BioTherapeutics reports Q1 results

Aeglea BioTherapeutics (NASDAQ: AGLE ): Q1 Non-GAAP EPS of -$0.57. More news on: Aeglea BioTherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

AGLE - SunTrust sees 90% upside in Relmada Therapeutics in premarket analyst action

Aeglea BioTherapeutics (NASDAQ: AGLE ) initiated with Overweight rating and $12 (60% upside) price target at Piper Sandler. More news on: Aeglea BioTherapeutics, Inc., Keros Therapeutics, Inc., Novo Nordisk A/S, Healthcare stocks news, Stocks on the move, , Read more ...

AGLE - Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

AUSTIN, Texas, April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for rare and other high-burden diseases, today announced the closing of its public offering ...
Previous 10 Next 10